Marshall University

Marshall Digital Scholar
Pharmaceutical Science and Research

Faculty Research

Spring 3-19-2015

The flavonoid nobiletin inhibits tumor growth and
angiogenesis of ovarian cancers via the Akt pathway
Jianchu Chen
Allen Y. Chen
Haizhi Huang
Xingqian Ye
William D. Rollyson
See next page for additional authors

Follow this and additional works at: http://mds.marshall.edu/sp_psr
Part of the Oncology Commons, and the Pharmacy and Pharmaceutical Sciences Commons
Recommended Citation
Chen J, Chen AY, Huang H, Ye X, Rollyson WD, Perry HE, Brown KC, Rojanasakul Y, Rankin GO, Dasgupta P, Chen YC. The
flavonoid nobiletin inhibits tumor growth and angiogenesis of ovarian cancers via the Akt pathway. International Journal of Oncology.
2015;46(6):2629-2638.

This Article is brought to you for free and open access by the Faculty Research at Marshall Digital Scholar. It has been accepted for inclusion in
Pharmaceutical Science and Research by an authorized administrator of Marshall Digital Scholar. For more information, please contact
zhangj@marshall.edu, martj@marshall.edu.

Authors

Jianchu Chen, Allen Y. Chen, Haizhi Huang, Xingqian Ye, William D. Rollyson, Haley E. Perry, Kathleen C.
Brown, Yon Rojanasakul, Gary O. Rankin, Piyali Dasgupta, and Yi Charlie Chen

This article is available at Marshall Digital Scholar: http://mds.marshall.edu/sp_psr/83

INTERNATIONAL JOURNAL OF ONCOLOGY 46: 2629-2638, 2015

The flavonoid nobiletin inhibits tumor growth and
angiogenesis of ovarian cancers via the Akt pathway
Jianchu Chen1,2, Allen Y. Chen3, Haizhi Huang1,2, Xingqian Ye1,
William D. Rollyson4, Haley E. Perry4, Kathleen C. Brown4,
Yon Rojanasakul3, Gary O. Rankin4, Piyali Dasgupta4 and Yi Charlie Chen2
1

College of Biosystems Engineering and Food Science, Fuli Institute of Food Science, Zhejiang University, P.R. China;
2
College of Science, Technology and Mathematics, Alderson Broaddus University, Philippi, WV 26416;
3
Department of Pharmaceutical Science, West Virginia University, Morgantown, WV 26506; 4Department of Pharmacology,
Physiology and Toxicology, Joan C. Edwards School of Medicine, Marshall University, Huntington, WV 25755, USA
Received February 10, 2015; Accepted March 19, 2015
DOI: 10.3892/ijo.2015.2946
Abstract. Despite its importance, the death rate of ovarian
cancer has remained unchanged over the past five decades,
demanding an improvement in prevention and treatment of
this malignancy. With no known carcinogens, targeted prevention is currently unavailable, and efforts in early detection of
this malignancy by screening biomarkers have failed. The
inhibition of angiogenesis, also known as angioprevention,
is a promising strategy to limit the growth of solid tumors,
including ovarian cancers. Nobiletin, a polymethoxy flavonoid
compound isolated from the tiansheng plant, has been shown
to inhibit the growth of multiple types of human cancers.
However, there are no reports involving the effect on nobiletin on human ovarian cancer. The present report shows that
nobiletin potently decreases the viability of ovarian cancer
cells in vitro. However, nobiletin does not affect the viability
of normal ovarian epithelial cells at <40 µM. The antitumor
activity of nobiletin was also observed in athymic mouse
models and in chicken chorioallantoic membrane (CAM)
models. The anti-neoplastic activity of nobiletin was due to its
ability to inhibit angiogenesis. We also studied the molecular
mechanisms by which nobiletin suppresses angiogenesis. We
observed that nobiletin inhibits secretion of the key angiogenesis mediators, Akt, HIF-1α, NF-κ B and vascular epithelial
growth factor (VEGF) by ovarian cancer cells. Transient transfection experiments showed that nobiletin inhibits production
of HIF-1α by downregulation of Akt. Such decreased levels
of HIF-1α were responsible for nobiletin-induced suppression
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of VEGF. Our data suggest that nobiletin may be a promising
anti-angiogenic agent relevant for therapy of ovarian cancers.
Introduction
Ovarian cancer is one of the most serious malignancies for
women in the world, ranking as the fifth leading cause of
cancer-related deaths (1) and the death rate of ovarian cancer
has not seen any remarkable changes for over five decades
in the USA (2). Due to a lack of effective biomarkers for
screening (3,4), nearly 60-70% of ovarian cancers are diagnosed at advanced stages (5), with a poor prognosis of ~30%
for a 5-year survival rate (6). These facts emphasize the
need for novel therapies to prevent and treat ovarian cancer.
Several lines of evidence indicate that nutritional compounds
display potent anticancer activity in many human cancers (5).
The identification of nutritional agents that can suppress the
growth and progression of ovarian cancer could lead to new
treatment modalities and improved patient outcomes for this
lethal malignancy.
Recent studies have focused on the anticancer activity of
flavonoids isolated from plants and animals. Flavonoids are
natural polyphenols present in a wide variety of fruits and
vegetables (7). Some flavonoids, such as apigenin, genistein
and catechin, have been shown to inhibit the growth of
ovarian, breast, colon, prostate and leukemia cancer cells
(8-17). Nobiletin (5,6,7,8,30,40-hexamethoxyflavone) is a
polymethoxyflavonoid found in citrus fruits such as Citrus
depressa and Citrus reticulate (18). Previous mammalian
in vivo studies show that nobiletin can suppress inflammation-associated tumorigenesis aberrant cell proliferation and
colon carcinogenesis (19-21). Nobiletin has been also shown
to suppress angiogenesis in vitro in human umbilical vein
endothelial cells. The anti-angiogenic activity of nobiletin
has been shown in chicken chorioallantoic membranes and in
zebrafish models (22,23). It has been revealed that nobiletin
exhibited a cell differentiation-modulating activity (24,25)
and inhibited the phosphorylation of MEK (26,27). Nobiletin
is a decreases metastasis of human fibrosarcoma HT-1080
cells and gastric cancers (27). The mitogen-activated protein
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kinase (MAPK) signaling pathway is a key regulator of
cell proliferation, survival and differentiation. The MAPK
pathway is constitutively activated in ovarian cancers via gain
of function mutations in Ras or Raf. In addition, mutations in
PI-3 kinase pathway have been implicated in the progression
of ovarian cancers. The hyperactivation of the MAP kinase
pathway facilitates the neoplastic transformation of ovarian
tumors. Selective MEK1 inhibitors have been shown to
suppress the growth of estrogen-responsive ovarian cancers.
Since nobiletin also functions as a MEK1 inhibitor we conjectured that perhaps it could suppress the growth of human
ovarian cancers. The growth-inhibitory activity of nobiletin
has yet to be studied in ovarian cancer. Our report fills this
void of knowledge and describes the anti-neoplastic activity of
nobiletin in human ovarian cancer. In this report, we show that
nobiletin decreases the viability of the human ovarian cancer
cell lines OVCAR-3 and CP-70. The growth-inhibitory effects
of nobiletin were observed at concentration as low as 5 µM.
Nobiletin had no effect on the viability of normal ovarian
epithelial cells at <40 µM. Therefore, it displayed a strong
selectivity for human ovarian cancer cells over normal ovarian
cells. Nobiletin potently decreased the growth rate of human
ovarian tumors xenografted in athymic mouse models and
chicken CAM models. The anticancer activity of nobiletin was
correlated with its anti-angiogenic and anti-apoptosis activity
in ovarian cancers. We also analyzed the signaling pathways
underlying the anti-angiogenic activity of nobiletin. The antiangiogenic activity of nobiletin was correlated with decreased
levels of Akt, HIF-1α, NF-κ B and vascular epithelial growth
factor (VEGF) in ovarian cancer cells. Taken together, our data
suggest that nobiletin may have applications in the therapy of
human ovarian cancer.
Materials and methods
Ethics statement. Male four-week-old athymic mice were
obtained from Charles River Laboratories and acclimatized
for one week. They were housed in autoclaved cages with
ad libitum access to food and water in HEPA-filtered racks
and closely monitored by animal facility staff. All procedures involving nude mice were conducted according to the
Animal Care and Use guidelines in a facility accredited by the
Association for Assessment and Accreditation of Laboratory
Animal Care (AAALAC) International and were approved by
the Institutional Animal Care and Use Committee (IACUC)
of Joan C. Edwards School of Medicine, Marshall University
(protocol no. 560).
Reagents, antibodies and constructs. Nobiletin was prepared
from a polymethoxyflavonoid mixture, which was provided
by Zhejiang Quzhou Tiansheng Plant Extraction Co. Ltd.
in China, containing ~60% nobiletin and tangeretin. The
polymethoxyflavonoid mixture was dissolved in methanoldimethyl sulfoxide (1:1), its concentration was 50 mg/ml, then
chromatographed with high-performance liquid chromatography (HPLC) (Waters) eluted with methanol-H2O (70:30) in
8 ml/min at room temperature, separated into two fractions,
collected individually, evaporated, obtained fraction I and
fraction II. Fraction I was identified as nobiletin (Fig. 1A)
by HPLC-MS, UV-vis chromatography and comparing peak

time with that of nobiletin sample from Sigma and previous
reports (data not shown). Its purity was >98%. Monoclonal
antibodies against HIF-1α, NF-κ B (p50), PTEN, c-Myc,
GAPDH, p-AKT, total AKT, p-mTOR and total mTOR were
purchased from Santa Cruz Biotechnology (Santa Cruz, CA,
USA). The secondary antibodies of anti-rabbit and anti-mouse
were purchased from Thermo Scientific (Pierce, Rockford,
IL, USA). The Hif-1α and mAkt plasmid constructs were
obtained from Addgene (www.addgene.org) (28).
Cell culture and treatment. Human ovarian cancer cell lines,
OVCAR-3 and A2780/CP70, were provided by Dr B. Jiang,
Department of Microbiology, Immunology, and Cell Biology,
West Virginia University. IOSE-364, normal ovarian surface
epithelial cells from healthy women, but immortalized with
SV40 T/t, were courtesy of Dr N. Auersperg at University
of British Columbia, Canada. All cells were maintained in
RPMI-1640 medium supplemented with 100 U/ml penicillin,
100 µg/ml streptomycin and 10% US-qualified fetal bovine
serum (Invitrogen, Grand Island, NY, USA) in a humidified
incubator with 5% CO2 at 37˚C. Nobiletin was dissolved
in dimethyl sulfoxide (DMSO) to make stock solutions of
100 mM and equal amount of DMSO was included in controls
for every experiment.
Cell proliferation. The effect of nobiletin on the viability of
ovarian cancer cells (OVCAR-3 and A2780/CP70) colorimetrically determined with a CellTiter 96 Aqueous One Solution
Cell Proliferation Assay kit from Promega (Madison, WI,
USA). The cells were seeded into 96-well plates at a density
of 5x103/well and incubated for 24 h at 37˚C. Subsequently,
the cells were treated with vehicle or varying concentrations
of nobiletin for another 24 h at 37˚C. After 24 h, the medium
was removed and cell viability was measured according to the
manufacturer's instructions. Each sample was measured in
triplicate. Cell viability was expressed as percentage of control
from three independent experiments.
Apoptosis assay. The apoptotic effects of nobiletin on ovarian
cancer cells were determined by FITC Annexin V Apoptosis
Detection Kit I from BD Biosciences. Cells were washed
with cold PBS twice and then were resuspended in binding
buffer at a concentration of 1x106/ml. An aliquot of 100 µl of
the cell solution (1x105 cells) was transferred to a 5-ml tissue
culture tube. Subsequently, 5 µl of FITC Annexin V and 5 µl
propidium iodide (PI) was added to the cells. The cells were
gently vortexed and incubated for 15 min at room temperature
in the dark. The next step involved the addition of 400 µl of
1X binding buffer to each tube. The samples were analyzed
by flow cytometry (Cytomic FC 500MCL) within 1 h. Three
independent experiments were assayed. Data represent mean
± SE from 3 independent experiments.
ELISA for VEGF. The levels of VEGF in cell culture supernatants were analyzed by a Quantikine Human VEGF
Immunoassay kit (R&D Systems, Minneapolis, MN, USA).
Cells (1x104/well) were seeded into 96-well plates and incubated overnight. Subsequently, the cells were treated with
nobiletin for 16 h in serum-free medium. Culture supernatants
were collected and spun down at 10,000 g at 4˚C. The superna-
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Figure 1. Structure of nobiletin.

tant was collected and stored at -70˚C. The amounts of VEGF
were measured following the manufacturer's instructions, and
normalized to cell numbers for each treatment. A total of three
independent experiments, each in triplicates, were assayed,
and the mean VEGF protein level from each triplicate was
used for statistical analysis.
Western blot analysis. Ovarian cancer cells (106) were seeded
in 60-mm dishes and incubated for 16 h before treated with
nobiletin for 24 h. The cells were washed with PBS, lysed in
100 µl mammalian protein extraction reagent including 1 l halt
protease, 1 µl phosphatase inhibitor and 2 µl EDTA (M-PER,
Pierce), according to the manufacturer's instructions. Total
protein levels were assayed with a BCA Protein Assay kit
(Pierce). Forty microgram of protein lysates was separated by
10% SDS-PAGE and transferred into nitrocellulose membrane
with a Mini-Protean 3 system (Bio-Rad Laboratories, Hercules,
CA, USA). The membranes were blocked in 5% milk in PBS
containing 0.1% Tween-20 for 1 h at room temperature. The
membranes were incubated with the appropriate dilutions of
the primary antibodies and secondary antibodies. The signal
obtained in the western blot experiments was detected by the
SuperSignal West Dura Extended Duration Substrate (Pierce
Biotechnologies). Protein bands were quantitated with NIH
ImageJ software, normalized by corresponding GAPDH or
total AKT, total mTOR bands, and expressed as percentages of
control. A total of three independent experiments were carried
out for statistical analysis.
Transient transfection and reporter assay. Transient transfection and reporter assay were modified from our published
report (28,29). Ovarian cancer cells were seeded in 96-well
plate at 10,000 cells/well and incubated overnight. For
transfection with HIF-1α /mAkt plasmids, cells were then
transfected with 0.05 µg VEGF luciferase reporter, 0-0.25 µg
HIF-1α/mAkt or SR-α (as vehicle) plasmids by 0.6 µl jetPRIME
reagent (VWR) for 4 h and removed the medium. Followed
by 16-h treatment with 0- or 40-µM nobiletin. The cells were
harvested and analyzed for luciferase activities with ONE-Glo
Luciferase Assay system (Promega) and detected by Lumat
LB9507 (Berthold Technologies). Total protein levels with a
BCA Protein Assay kit (Pierce), and the activities of VEGF
reporter were normalized by corresponding total protein levels
for statistical analysis. The experiments were conducted three
times.
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Chicken embryo chorioallantoic membrane (CAM) assay.
The A2780 cells at grown to 70% confluence, were harvested,
washed with PBS and re-suspended in serum-free medium.
Aliquots of the cells (0.1 ml, 2x107/ml) were mixed with 0.1 ml
of Matrigel (BD Bioscience, San Jose, CA, USA), supplemented with 0 or 20 µM nobiletin, pre-gelled on an autoclaved
silicone mat for 30-40 min, and implanted onto the CAM of
9-day-old chicken embryo. Chicken embryos were incubated
for 4-5 days, photographed for Matrigel implant, and counted
for branching blood vessels. Angiogenesis was evaluated by
normalizing number of branching vessels to that of control
CAM. A total of 10 eggs were assayed for each group.
Antitumor studies in athymic mice. Twenty-four week-old male
nude mice were obtained from Charles River Laboratories and
acclimatized for one week. They were housed in autoclaved
cages with ad libitum access to food and water in HEPAfiltered racks and closely monitored by animal facility staff.
All procedures were conducted according to the Animal Care
and Use guidelines in a facility accredited by the Association
for Assessment and Accreditation of Laboratory Animal
Care (AAALAC) International and were approved by the
Institutional Animal Care and Use Committee (IACUC) of
Joan C. Edwards School of Medicine, Marshall University
(protocol no. 560).
CP70 cells were harvested and re-suspended in a 1:1
(v/v) solution of serum-free media and Matrigel matrix
(BD Biosciences). Two million cells in 100 µl were injected
subcutaneously between the scapulae of each mouse (30).
After the tumors reached 100 mm3, the mice were randomized and divided into two groups comprising of ten mice each.
The treatment group (N=10) was fed AIN-76A diet with 5%
lipid level containing 100 mg nobiletin/kg food. The control
group (N=10) was fed AIN76A diet containing vehicle. Mice
were weighed once per week. Their food consumption was
monitored daily. Tumor volumes were calculated as (l x w2)/2
(31,32).
Statistical analysis. Results are expressed as mean ± standard
error of mean (SEM) using Microsoft Excel (Windows 8).
Statistical assessment was carried out with the program
system of SPSS (Version 16.0 for Windows). The results
were analyzed using one-way analysis of variance (ANOVA)
and post hoc test (2-sided Dunnett's test) to test both overall
differences and specific differences between each treatment
and control. A P-value of <0.05 was considered statistically
significant.
Results
Effect of nobiletin on ovarian cancer cell viability. The
treatment of OVCAR-3 and CP70 ovarian cancer cells with
nobiletin caused a concentration-dependent decrease in cell
viability over 24 h. Beginning at a concentration of 5 µM
nobiletin, OVCAR-3 cell viability consistently decreased
from 95±1 to 28±4% at a concentration of 160 µM nobiletin
(P<0.01) (Fig. 2A). Similarly, CP70 cell viability was also
suppressed with different concentration. At a concentration of
5 µM nobiletin cell viability was 96±1% (P<0.05), that was
gradually inhibited to 26±3% by a 160-µM nobiletin treatment
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Figure 2. Nobeletin decreased the viability and induced apoptosis of human ovarian cancer cells in a concentration-dependent manner. (A) Cell viability
assays showed that the treatment of OVCAR-3 cells with varying concentrations of nobiletin caused a decrease in cell viability. (B) The cell viability assay
was repeated in A2780/CP70 cells. (C) Cell viability results were obtained in IOSE-364 cells. (D) Apoptosis assay showed that nobiletin induced apoptosis of
A2780/CP70 ovarian cancer cells. Data represent mean ± SE from 3 independent experiment. *P<0.05 as compared to control. **P<0.01 as compared to control.

(P<0.01) (Fig. 2B). We also examined the growth inhibitory activity of nobiletin on IOSE-364 normal ovarian cells
(Fig. 2C). We observed that nobiletin had a lower growthinhibitory activity in IOSE-364 cells than in A2780 ovarian
cancer cells. Therefore, our data suggest that nobiletin is
somewhat more selective towards ovarian cancer cells than
normal cells.
Effect of nobiletin on ovarian cancer cell apoptosis. We
ascertained that the growth inhibitory effects of nobeletin
were due to cellular apoptosis. Annexin FITC assays
revealed that nobiletin induced apoptosis in CP70 ovarian
cancer cells in a concentration-dependent manner (Fig. 2D).
CP70 cell apoptosis was 13±1% when it was not treated with
nobiletin, which was significant increased at a concentration
of 10 µM nobiletin (26±2%). CP70 cell apoptosis was gradually increased to 88±2% by a 160-µM nobiletin treatment
(P<0.01).
Effect of nobiletin on angiogenesis and growth of the tumor.
To assess whether nobiletin inhibits the growth of human
ovarian cancers in vivo, we used the CAM and athymic
mouse models to study the effect of nobiletin on the growth
rate of human ovarian cancer cells in vivo. The administration of 20 µM nobiletin significantly attenuated (P<0.01)
the growth of OVCAR human ovarian tumors implanted

on CAM (Fig. 3A and B). We counted the number of blood
vessels to assess whether nobiletin was suppressing the
growth of ovarian tumors by inhibition of angiogenesis. The
chicken CAM experiment was repeated using A2780 cells
and similar results were obtained. We observed that the
treatment of OVCAR and A2780 cells with 20 µM nobiletin
was able to inhibit angiogenesis. The implanted cancer
cells grow to a tumor weight of 58±5 mg, with 29±4 blood
vessels counted. Inclusion of 20 µM nobiletin in this implant,
however, reduced tumor growth down to 34±3 mg (P<0.01)
and inhibited blood vessel development to 19±2 (P<0.05). We
speculated that the effect of nobiletin on the promotion of
cancer cell apoptosis and inhibition of angiogesis lead to the
growth attenuation of tumors implanted on CAM. A typical
image (Fig. 3C) is shown to contrast the tumors with or
without nobiletin in terms of both tumor size and angiogenesis. The great effect of nobiletin on inhibiting tumor growth
was conformed in vivo using an athymic mouse model, where
they exhibited smaller tumor size (Fig. 3D). The tumors
implanted on mice grow to a volume of 2450 mm3 at the 15th
day. However, the treatment of nobiletin (100 mg/kg food)
inhibited tumor growth to 300 mm3.
Effect of nobiletin on VEGF expression. Our results showed
that nobiletin significantly inhibited the expression of vascular
endothelial grow factor (VEGF) in ovarian cancer cells,

INTERNATIONAL JOURNAL OF ONCOLOGY 46: 2629-2638, 2015

2633

Figure 3. Nobiletin inhibits tumor growth and angiogenesis in CAM and athymic mouse models. Chicken chorioallantoic membrane (CAM) assay showing
tumor without nobiletin treatment (A), treated with 20 µM nobiletin (B). CAM assays showed that 20 µM nobiletin suppressed the growth of blood vessels and
A2780/CP70 tumors xenografted on chicken CAM relative to vehicle treated tumors (C). After 5 days of treatment, the tumors were excised, and the blood
vessels were counted by phase contrast microscopy. Angiogenesis was evaluated by normalizing number of branching vessels to that of control CAM. The data
are presented as mean ± SEM (n=10 eggs/group) (C). Nobiletin treatment also significantly inhibited tumor growth in the athymic mice (D).

Figure 4. Nobiletin induces a concentration-dependent decrease of VEGF production from human ovarian cancer cells. The human ovarian cancer cell line
OVCAR-3 (A), and A2780/CP70 (B) were treated with varying concentrations of nobiletin for 16 h. Subsequently, the VEGF levels in the supernatant was
measured by ELISA. A total of three independent experiments, each in triplicates, were assayed, and the mean VEGF protein level from each duplicate was
used for statistical analysis. *P<0.05 as compared to control. **P<0.01 as compared to control.

and this inhibition effect was enhanced with the increase of
nobiletin concentration (Fig. 4). In both OVCAR-3 and A2780/
CP-70 cells, the inhibitory effect of nobiletin on VEGF secretion reached a significant level when its concentration was
>20 µM. The levels of secreted VEGF protein in OVCAR-3
cell culture supernates were downregulated to 77±2% at a
concentration of 10 µM nobiletin (P<0.01) and to 28±1% at a

concentration of 160 µM nobiletin (P<0.01) (Fig. 4A). Similarly
the levels of secreted VEGF protein in CP70 cells ranged from
66±2% (20 µM) to 16±2% (160 µM) with respect to different
nobiletin concentration (Fig. 4B).
Signaling pathways underline the growth inhibiting activity
of nobiletin. HIF-1α is one of the key factors for the regula-
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Figure 5. Nobiletin regulates several intracellular signaling pathways in human OVCAR-3 and CP-70 ovarian cells. (A) Nobiletin decreases the levels of
HIF-1α in OVCAR-3 and CP-70 human ovarian cells. Protein bands were quantitated, normalized by corresponding GAPDH bands, and expressed as
percentages of control (bar graph below the panel). (B) Nobiletin lowers the phosphorylation of Akt (Ser4) in OVCAR-3 and CP-70 cells. The levels of total Akt
are not affected by nobiletin treatment. The bar graph below the panel represents densitometric analysis of the immunoblotting data. (C) Nobiletin decreases
NF-κB expression in both ovarian cancer cell lines. (D) Nobiletin had no effect on expression of c-Myc, PTEN, mTOR proteins. Nobiletin had no effect on
the phosphorylation of mTOR protein in either ovarian cancer cell line. A total of three independent experiments were carried out for statistical analysis. Data
represent mean ± SE from 3 independent experiment. *P<0.05 as compared to control. **P<0.01 as compared to control.

tion of VEGF expression. As shown in Fig. 5A, nobiletin had a
certain impact on HIF-1α expression of ovarian cancer cells.
For OVCAR-3, 20-µM nobiletin treatment led to inhibition
of HIF-1α protein to 78±6% by 24 h of treatment. Higher
concentrations of nobiletin resulted in greater inhibition,
with the levels of HIF1-α protein down to 57±3% by 40-µM
nobiletin treatment (P<0.01) and 23±3% by 80-µM nobiletin
treatment (P<0.01). However, for CP70, HIF-1α expression
was slightly enhanced (118±2%) when the concentration
of nobiletin was <20 µM and was significantly inhibited
(47±2%) when its concentration was 80 µM (P<0.01). It seems
CP70 cells were more resistant to the effect of nobiletin than
OVCAR-3 cells on HIF-1α expression.

Nobiletin inhibited phosphorylation of AKT, which is
known to be the major signal for cell survival and proliferation (33). As shown in Fig. 5B, nobiletin decreased AKT
phosphorylation for both OVCAR-3 and CP70 ovarian cancer
cells. P-AKT level was downregulated from 70±2% by 20-µM
nobiletin treatment to 29±4% by 80-µM nobiletin treatment in
OVCAR-3 cells. The phosphorylation of AKT was also inhibited from 69±1% by the 20-µM nobiletin treatment to 49±1%
by 40-µM nobiletin treatment in CP70 cells. However, the
effect of nobiletin on the inhibition of AKT phosphorylation in
C70 cells was decreased when treated with 160-µM nobiletin.
Again, it seems CP70 cells were more resistant to the effect of
nobiletin than OVCAR-3 cells on AKT phosphorylation.

INTERNATIONAL JOURNAL OF ONCOLOGY 46: 2629-2638, 2015
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Figure 7. Proposed pathway for the nobiletin effect on tumor growth and
angiogenesis.

Figure 6. Forcing expression of HIF-1α protein (A) and Akt protein (B)
reversed the effect of nobiletin on VEGF transcriptional activation.
OVCAR-3 and A2780/CP70 cancer cells were seeded in a 96-well plate at
10,000 cells/well and incubated overnight. The cells were then transfected
with 0.05 µg VEGF (Hif-1α) luciferase reporter, 0-0.25 µg HIF-1α (AKT)
or SR-α plasmids by 0.6 µl jetPRIME reagent for 4 h, followed by 16-h treatment with 0 or 40 µM nobiletin. The cells were harvested and analyzed for
luciferase and total protein levels, and the levels of VEGF (Hif-1α) reporter
were normalized by corresponding total protein levels. Data represent mean
± SE from 3 independent experiment. *P<0.05 as compared to control.
**
P<0.01 as compared to control.

NF-κ B is a common transcription factor that is related to
many signal transduction pathways of cancer cell proliferation
and angiogenesis (34,35). The effect of nobiletin on NF-κ B
expression is shown in Fig. 5C. Results showed that nobiletin
had an impact on NF-κ B (p50) expression. The level of NF-κ B
(p50) decreased with the increase of nobiletin concentration
in OVCAR-3 and CP-70 cells. For OVCAR-3, the inhibitory
effect reached a significant level (87±1%) when the concentration of nobiletin was 20 µM (P<0.01). In CP70, NF-κ B (p50)
level reduced with the increase of nobiletin concentration, and
it reached a significant level when the nobiletin concentration
was 20 (88±1%) and 80 µM (57±6%) (P<0.05).
c-Myc is a transcription factor that plays a role in cell cycle
progression, apoptosis and cellular transformation. Unlike
kaempferol, which inhibited c-Myc protein expression (35), our
results indicated that nobiletin did not inhibit c-Myc expression in ovarian cancer cells (Fig. 5D). Its mechanism needs to
be further investigated. PTEN acts as a tumor suppressor gene

which is involved in the regulation of the cell cycle, preventing
cells from growing and dividing too rapidly (36). The protein
of mTOR is a serine/threonine protein kinase that regulates
cell growth, cell proliferation, cell motility, cell survival,
protein synthesis, and transcription (37). Results also showed
that nobiletin had no significant effect on PTEN and p-mTOR
expression in ovarian cancer OVCAR-3 and CP-70 (Fig. 5D).
Nobiletin inhibits VEGF by regulating HIF-1α expression and
Akt signaling. To see that HIF-1 is not only regulated by nobiletin treatment, but also plays a role in the nobiletin inhibition
on VEGF expression, ovarian cancer cells were transfected
with the VEGF-promoter reporter together with HIF-1 plasmids. While nobiletin treatment significantly inhibited VEGF
transcriptional activation, this inhibition was concentrationdependent and significantly reversed by forced expression of
HIF-1α protein (Fig. 6A).
The role played by Akt signaling in the nobiletin regulation of VEGF expression was investigated in both ovarian
cell lines. It was found that the phosphorylation of Akt was
significantly inhibited by 2-h nobiletin treatment (Fig. 6B).
After transfecting with VEGF-promoter reporter and mAkt
plasmids, VEGF transcriptional activation was significantly
reduced by nobiletin treatment in both ovarian cancer cell
types, and this effect was significantly reversed by forced
expression of Akt protein (Fig. 6B).
Discussion
Angiogenesis is a necessary condition for sustained tumor
growth. Tumor cells take in nutrition and oxygen through the
generated blood vessels, which produce substances needed for
growth (38). Angiogenesis plays a central role in the development and progression of ovarian cancer (39). Histological
studies demonstrated that ovarian tumors are richly vascu-
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larized. A correlation between microvascular count and
biological aggressiveness was also found (40,41). Vascular
endothelial growth factor (VEGF), as a key regulator of
angiogenesis in ovarian cancer, is involved in various steps
of ovarian carcinogenesis (42,43). VEGF plays a central role
in tumor vasculature development and maintenance. VEGF
expression promotes angiogenesis, thereby stimulating tumor
growth and metastasis. Hypoxia-inducible factor 1α (HIF-1α)
is a heterodimeric basic helix-loop-helix protein that directly
activates transcription of VEGF gene by binding to a HRE
(44). Previous studies showed that nobiletin inhibited angiogenesis in human umbilical vein endothelial cells (HUVECs)
and zebrafish models (22,23,45). Similarly, the results showed
that nobiletin effectively inhibited angiogenesis in ovarian
cancer cells planted on chicken embryos models, indicating
its potential to inhibit tumor growth in vivo.
While VEGF expression is an important factor in tumor
growth and metastasis, HIF-1α is one of the key factors for
VEGF expression. Previous studies (46,47) showed that the
anticancer flavonoid compound kaempferol inhibited angiogenesis in ovarian cancer cells by downregulating HIF-1α
expression. This is consistent with our study, indicating that
the nobiletin inhibitory effects on angiogenesis can be traced
back to suppression of HIF-1α expression. However, contradictory results were found in zebrafish models which showed that
nobiletin increased mRNA levels of VEGF (22). This could be
because nobiletin induced anti-angiogenesis through different
mechanism in the two kinds of cells. PI3 kinase/Akt pathways
could attenuate ovarian carcinoma through mediating angiogenesis and vascular permeability (48). In addition, taking
into consideration previous studies that HIF-1α is related to
the PI3 kinase/Akt signaling pathways (30-32), we tested if
nobiletin inhibited expression of VEGF through PI3K/AKT
pathways. Our results revealed that nobiletin significantly
inhibited the phosphorylation of Akt. The inhibitory effect of
nobiletin on Akt phosphorylation was more pronounced than
on HIF-1α expression shown above. Previous studies showed
that nobiletin suppressed PI3K/Akt pathways in human
HepG2 (49). It was similar to our findings that nobiletin
inhibited angiogenesis mainly through Akt pathways which
results in the downregulation of VEGF expression (Fig. 6B).
The mechanism by which nobiletin inhibits the PI3K/Akt
signaling pathway is not fully understood. However, it has
been shown that nobiletin suppressed invasion and migration
of human gastric adenocarcinoma AGS cells through FAK/
PI3K/Akt pathways (50).
Some researchers found that Akt pathways regulates the
expression, activation and translocation of NF-κ B (51-53).
Suppression of NF-κ B in tumor samples also inhibits proliferation, causes apoptosis, indicating the crucial role of NF-κ B
in cell proliferation and survival. We consider that it plays an
important role on the nobiletin-induced apoptosis in A2780/
CP70 cells. It was also found that Hif-1α promoter is responsive to selective NF-κ B subunits, indicating that NF-κ B is a
direct modulator of Hif-1α expression (54). NF-κ B, which is
related to many signal transduction pathways of cancer cells
(34), has been identified in tumors of epithelial origin such as
breast, colon, lung and ovarian cancers (55). Recent research
suggested the importance of NF-κ B in the propagation of
ovarian cancer cell lines (56). It was also found that NF-κ B

had a relationship with angiogenesis; that is, NF-κ B regulates
c-Myc expression. Overexpression of NF-κ B removed the
kaempferol inhibitory effect on c-Myc expression (35). Our
results showed that the effect of nobiletin on NF-κ B in ovarian
cancer cells varies with cancer cells. Similar to the results found
in AKT phosphorylation, NF-κ B levels in the OVCAR-3 cells
were more sensitive than those in the CP70 line. Nevertheless,
nobiletin treatment significantly reduced NF-κ B expression
in both cell lines in a concentration-dependent manner. As
previous study showed NF-κ B have been linked to regulation
of VEGF production (57), we conclude nobiletin antagonizes
VEGF expression through NF-κ B (Fig. 7).
The proposed mechanism by which nobiletin hampers
angiogenesis involves lowering concentrations of VEGF regulators, namely HIF-1α and NF-κ B (Fig. 7). We found nobiletin
to have little effect on c-Myc, PTEN, and p-mTOR expression,
which indicates that nobiletin does not inhibit expression of
VEGF through PTEN/mTOR pathways, neither is c-Myc the
key protein that is affected by nobiletin treatment in ovarian
cells. Noteworthy, both HIF-1α and Akt were demonstrated to
play direct roles in VEGF secretion. Overexpression of either
protein in the presence of nobiletin neutralized its VEGF
diminishing effects. Since Akt phosphorylation is intimately
linked to HIF-1α activation, it is likely nobiletin exerts its
cancer fighting properties through blocking Akt phosphorylation. Impeding Akt activity likewise reduces HIF-1α and
NF-κ B levels, subsequently dropping VEGF production and
obstructing angiogenesis. Considering all the evidence, we
believe this is the central pathway through which nobiletin
mediates its tumor limiting effects.
Importantly, our in vitro research conducted agrees with
both of our in vivo models. In our CAM model, nobiletin treatment significantly reduced not only the tumor size but also the
number of blood vessels, confirming its potency in countering
angiogenesis. Furthermore, nobiletin also suppressed tumor
growth rates of CP-70 human ovarian cancer cells in the nude
mouse model. The administration of nobiletin did not cause
any discomfort in mice. The weights of mice, their food intake,
water intake were unaffected by the administration of nobiletin (data not shown).
The challenge of conventional chemotherapy in ovarian
cancer is that chemotherapeutic drugs are also toxic to
normal ovarian epithelial cells. We find that nobiletin potently
inhibits the viability of human ovarian cancer cells, and has
minimal effects of the viability of normal ovarian cells. The
selective inhibitory effect might be at least partly attributed
to the apoptosis and anti-angiogenesis induced by nobiletin.
Overexpression and activation of Akt, which results in the
survival of cancer cells that normally undergo apoptosis (58),
occurs in different kinds of cancers, such as gastric, lung,
panacreatic and ovarian cancer (59). Nobiletin inhibits overian
cancer cells selectively, possibly due to its effect on the phosphorylation of Akt.
Platinum drugs have been most frequently applied for
the treatment of cancers including ovarian cancer. However,
acquired resistance to conventional platinum based chemotherapy has become a major impediment in cancer treatment.
Novel therapies that can reverse drug resistance or kill drug
resistant ovarian cancer cells directly are highly desired.
Flavonoid compounds like tangeretin (60) and kaempferol
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(61) have been shown to sensitize ovarian cancer cells to
the apoptotic effects of cisplatin. Since nobiletin selectively
inhibits ovarian cancer cells, it is expected that nobiletin may
be useful both as a single agent as well as in combination
therapies in the treatment of ovarian cancers.
Acknowledgements
This study was supported by a grant of the West Virginia
Experimental Program to Stimulate Competitive Research
and NIH grants (5P20RR016477 and 8P20GM103434) from
the National Institutes of Health awarded to the West Virginia
IDeA Network of Biomedical Research Excellence.
References
1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E,
Feuer EJ and Thun MJ; American Cancer Society: Cancer statistics, 2004. CA Cancer J Clin 54: 8-29, 2004.
2. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA
Cancer J Clin 60: 277-300, 2010.
3. Bast RC Jr, Xu FJ, Yu YH, Barnhill S, Zhang Z and Mills GB:
CA 125: The past and the future. Int J Biol Markers 13: 179-187,
1998.
4. Winstead ER: Ovarian cancer study raises questions about
developing markers for early detection. NCI cancer bulletin
[On-line serial], 8 (5). Available ncicancerbulletin@mail.nih.gov
Message: NCI Cancer Bulletin, March 8, 2011.
5. Fishman DA and Schwartz PE: Current approaches to diagnosis
and treatment of ovarian germ cell malignancies. Curr Opin
Obstet Gynecol 6: 98-104, 1994.
6. Greenlee RT, Hill-Harmon MB, Murray T and Thun M: Cancer
statistics, 2001. CA Cancer J Clin 51: 15-36, 2001.
7. Bosetti C, Rossi M, McLaughlin JK, Negri E, Talamini R,
Lagiou P, Montella M, Ramazzotti V, Franceschi S and
LaVecchia C: Flavonoids and the risk of renal cell carcinoma.
Cancer Epidemiol Biomarkers Prev 16: 98-101, 2007.
8. Bosetti C, Bravi F, Talamini R, Parpinel M, Gnagnarella P,
Negri E, Montella M, Lagiou P, Franceschi S and La Vecchia C:
Flavonoids and prostate cancer risk: A study in Italy. Nutr Cancer
56: 123-127, 2006.
9. Theodoratou E, Kyle J, Cetnarskyj R, Farrington SM, Tenesa A,
Barnetson R, Porteous M, Dunlop M and Campbell H: Dietary
flavonoids and the risk of colorectal cancer. Cancer Epidemiol
Biomarkers Prev 16: 684-693, 2007.
10. Adhami VM, Malik A, Zaman N, Sarfaraz S, Siddiqui IA,
Syed DN, Afaq F, Pasha FS, Saleem M and Mukhtar H: Combined
inhibitory effects of green tea polyphenols and selective cyclooxygenase-2 inhibitors on the growth of human prostate cancer
cells both in vitro and in vivo. Clin Cancer Res 13: 1611-1619,
2007.
11. Choi EJ, Kim T and Lee MS: Pro-apoptotic effect and cytotoxicity of genistein and genistin in human ovarian cancer SK-OV-3
cells. Life Sci 80: 1403-1408, 2007.
12. Seo HS, DeNardo DG, Jacquot Y, Laïos I, Vidal DS,
Zambrana CR, Leclercq G and Brown PH: Stimulatory effect
of genistein and apigenin on the growth of breast cancer cells
correlates with their ability to activate ER alpha. Breast Cancer
Res Treat 99: 121-134, 2006.
13. Fang J, Zhou Q, Liu LZ, Xia C, Hu X, Shi X and Jiang BH:
Apigenin inhibits tumor angiogenesis through decreasing
HIF-1alpha and VEGF expression. Carcinogenesis 28: 858-864,
2007.
14. Birt DF, Hendrich S and Wang W: Dietary agents in cancer
prevention: Flavonoids and isoflavonoids. Pharmacol Ther 90:
157-177, 2001.
15. Gossner G, Choi M, Tan L, Fogoros S, Griffith KA, Kuenker M
and Liu JR: Genistein-induced apoptosis and autophagocytosis
in ovarian cancer cells. Gynecol Oncol 105: 23-30, 2007.
16. Spinella F, Rosanò L, Di Castro V, Decandia S, Albini A,
Nicotra MR, Natali PG and Bagnato A: Green tea polyphenol
epigallocatechin-3-gallate inhibits the endothelin axis and downstream signaling pathways in ovarian carcinoma. Mol Cancer
Ther 5: 1483-1492, 2006.

2637

17. Brusselmans K, Vrolix R, Verhoeven G and Swinnen JV:
Induction of cancer cell apoptosis by flavonoids is associated
with their ability to inhibit fatty acid synthase activity. J Biol
Chem 280: 5636-5645, 2005.
18. Nogata Y, Sakamoto K, Shiratsuchi H, Ishii T, Yano M and
Ohta H: Flavonoid composition of fruit tissues of citrus species.
Biosci Biotechnol Biochem 70: 178-192, 2006.
19. Murakami A, Nakamura Y, Torikai K, Tanaka T, Koshiba T,
Koshimizu K, Kuwahara S, Takahashi Y, Ogawa K, Yano M, et al:
Inhibitory effect of citrus nobiletin on phorbol ester-induced skin
inflammation, oxidative stress, and tumor promotion in mice.
Cancer Res 60: 5059-5066, 2000.
20. Kohno H, Yoshitani S, Tsukio Y, Murakami A, Koshimizu K,
Yano M, Tokuda H, Nishino H, Ohigashi H and Tanaka T: Dietary
administration of citrus nobiletin inhibits azoxymethane-induced
colonic aberrant crypt foci in rats. Life Sci 69: 901-913, 2001.
21. Suzuki R, Kohno H, Murakami A, Koshimizu K, Ohigashi H,
Yano M, Tokuda H, Nishino H and Tanaka T: Citrus nobiletin
inhibits azoxymethane-induced large bowel carcinogenesis in
rats. Biofactors 22: 111-114, 2004.
22. Lam KH, Alex D, Lam IK, Tsui SK, Yang ZF and Lee SM:
Nobiletin, a polymethoxylated flavonoid from citrus, shows antiangiogenic activity in a zebrafish in vivo model and HUVEC
in vitro model. J Cell Biochem 112: 3313-3321, 2011.
23. Kunimasa K, Ikekita M, Sato M, Ohta T, Yamori Y, Ikeda M,
Kuranuki S and Oikawa T: Nobiletin, a citrus polymethoxyflavonoid, suppresses multiple angiogenesis-related endothelial cell
functions and angiogenesis in vivo. Cancer Sci 101: 2462-2469,
2010.
24. Kunimasa K, Kuranuki S, Matsuura N, Iwasaki N, Ikeda M, Ito A,
Sashida Y, Mimaki Y, Yano M, Sato M, et al: Identification
of nobiletin, a polymethoxyf lavonoid, as an enhancer of
adiponectin secretion. Bioorg Med Chem Lett 19: 2062-2064,
2009.
25. Saito T, Abe D and Sekiya K: Nobiletin enhances differentiation and lipolysis of 3T3-L1 adipocytes. Biochem Biophys Res
Commun 357: 371-376, 2007.
26. Miyata Y, Sato T, Yano M and Ito A: Activation of protein
kinase C βII/ε-c-Jun NH2-terminal kinase pathway and inhibition of mitogen-activated protein/extracellular signal-regulated
kinase 1/2 phosphorylation in antitumor invasive activity
induced by the polymethoxy flavonoid, nobiletin. Mol Cancer
Ther 3: 839-847, 2004.
27. Miyata Y, Sato T, Imada K, Dobashi A, Yano M and Ito A: A
citrus polymethoxyflavonoid, nobiletin, is a novel MEK inhibitor
that exhibits antitumor metastasis in human fibrosarcoma
HT-1080 cells. Biochem Biophys Res Commun 366: 168-173,
2008.
28. Luo H, Li B, Li Z, Cutler SJ, Rankin GO and Chen YC:
Chaetoglobosin K inhibits tumor angiogenesis through
downregulation of vascular epithelial growth factor-binding
hypoxia-inducible factor 1α. Anticancer Drugs 24: 715-724,
2013.
29. Fang J, Cao Z, Chen YC, Reed E and Jiang BH: 9- β -D-Arabino
furanosyl-2-fluoroadenine inhibits expression of vascular
endothelial growth factor through hypoxia-inducible factor-1
in human ovarian cancer cells. Mol Pharmacol 66: 178-186,
2004.
30. Blancher C, Moore JW, Robertson N and Harris AL: Effects of
ras and von Hippel-Lindau (VHL) gene mutations on hypoxiainducible factor (HIF)-1α, HIF-2α, and vascular endothelial
growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway. Cancer Res 61:
7349-7355, 2001.
31. Laughner E, Taghavi P, Chiles K, Mahon PC and Semenza GL:
HER2 (neu) signaling increases the rate of hypoxia-inducible
factor 1α (HIF-1α) synthesis: Novel mechanism for HIF-1mediated vascular endothelial growth factor expression. Mol
Cell Biol 21: 3995-4004, 2001.
32. Stiehl DP, Jelkmann W, Wenger RH and Hellwig-Bürgel T:
Normoxic induction of the hypoxia-inducible factor 1alpha by
insulin and interleukin-1beta involves the phosphatidylinositol
3-kinase pathway. FEBS Lett 512: 157-162, 2002.
33. Miura T, Chiba M, Kasai K, Nozaka H, Nakamura T, Shoji T,
Kanda T, Ohtake Y and Sato T: Apple procyanidins induce
tumor cell apoptosis through mitochondrial pathway activation
of caspase-3. Carcinogenesis 29: 585-593, 2008.
34. Jeong WS and Kong ANT: Biological properties of monomeric
and polymeric catechins: Green tea catechins and procyanidins.
Pharm Biol 42 (s1): 84-93, 2004.

2638

Chen et al: Nobiletin inhibits ovarian cancer growth

35. Luo H, Rankin GO, Juliano N, Jiang BH and Chen YC:
Kaempferol inhibits VEGF expression and in vitro angiogenesis
through a novel ERK-NFκ B-c-Myc-p21 pathway. Food Chem
130: 321-328, 2012.
36. Chu EC and Tarnawski AS: PTEN regulatory functions in tumor
suppression and cell biology. Med Sci Monit 10: RA235-RA241,
2004.
37. Hay N and Sonenberg N: Upstream and downstream of mTOR.
Genes Dev 18: 1926-1945, 2004.
38. Ferrara N: Vascular endothelial growth factor as a target for
anticancer therapy. Oncologist 9 (Suppl 1): 2-10, 2004.
39. Ramakrishnan S, Subramanian IV, Yokoyama Y and Geller M:
Angiogenesis in normal and neoplastic ovaries. Angiogenesis 8:
169-182, 2005.
40. Hazelton D, Nicosia RF and Nicosia SV: Vascular endothelial
growth factor levels in ovarian cyst fluid correlate with malignancy. Clin Cancer Res 5: 823-829, 1999.
41. Alvarez AA, Krigman HR, Whitaker RS, Dodge RK and
Rodriguez GC: The prognostic significance of angiogenesis
in epithelial ovarian carcinoma. Clin Cancer Res 5: 587-591,
1999.
42. Duyndam MC, Hilhorst MC, Schlüper HM, Verheul HM,
van Diest PJ, Kraal G, Pinedo HM and Boven E: Vascular endothelial growth factor-165 overexpression stimulates angiogenesis
and induces cyst formation and macrophage infiltration in human
ovarian cancer xenografts. Am J Pathol 160: 537-548, 2002.
43. Hefler LA, Mustea A, Könsgen D, Concin N, Tanner B, Strick R,
Heinze G, Grimm C, Schuster E, Tempfer C, et al: Vascular
endothelial growth factor gene polymorphisms are associated
with prognosis in ovarian cancer. Clin Cancer Res 13: 898-901,
2007.
44. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD
and Semenza GL: Activation of vascular endothelial growth
factor gene transcription by hypoxia-inducible factor 1. Mol Cell
Biol 16: 4604-4613, 1996.
45. Lam IK, Alex D, Wang YH, Liu P, Liu AL, Du GH and Lee SM:
In vitro and in vivo structure and activity relationship analysis
of polymethoxylated flavonoids: Identifying sinensetin as a
novel antiangiogenesis agent. Mol Nutr Food Res 56: 945-956,
2012.
46. Luo H, Rankin GO, Liu L, Daddysman MK, Jiang BH and
Chen YC: Kaempferol inhibits angiogenesis and VEGF expression through both HIF dependent and independent pathways in
human ovarian cancer cells. Nutr Cancer 61: 554-563, 2009.
47. Jiang BH and Liu LZ: AKT signaling in regulating angiogenesis.
Curr Cancer Drug Targets 8: 19-26, 2008.
48. Hu L, Hofmann J and Jaffe RB: Phosphatidylinositol 3-kinase
mediates angiogenesis and vascular permeability associated with
ovarian carcinoma. Clin Cancer Res 11: 8208-8212, 2005.

49. Shi MD, Liao YC, Shih YW and Tsai LY: Nobiletin attenuates
metastasis via both ERK and PI3K/Akt pathways in HGF-treated
liver cancer HepG2 cells. Phytomedicine 20: 743-752, 2013.
50. Lee YC, Cheng TH, Lee JS, Chen JH, Liao YC, Fong Y, Wu CH
and Shih YW: Nobiletin, a citrus flavonoid, suppresses invasion
and migration involving FAK/PI3K/Akt and small GTPase
signals in human gastric adenocarcinoma AGS cells. Mol Cell
Biochem 347: 103-115, 2011.
51. Kar S, Palit S, Ball WB and Das PK: Carnosic acid modulates
Akt/IKK/NF- κ B signaling by PP2A and induces intrinsic
and extrinsic pathway mediated apoptosis in human prostate
carcinoma PC-3 cells. Apoptosis 17: 735-747, 2012.
52. Kim MO, Moon DO, Heo MS, Lee JD, Jung JH, Kim SK,
Choi YH and Kim GY: Pectenotoxin-2 abolishes constitutively
activated NF-κ B, leading to suppression of NF-κ B related gene
products and potentiation of apoptosis. Cancer Lett 271: 25-33,
2008.
53. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM and
Donner DB: NF-κ B activation by tumour necrosis factor requires
the Akt serine-threonine kinase. Nature 401: 82-85, 1999.
54. van Uden P, Kenneth NS and Rocha S: Regulation of hypoxiainducible factor-1α by NF-kappaB. Biochem J 412: 477-484,
2008.
55. Karin M: Nuclear factor-kappaB in cancer development and
progression. Nature 441: 431-436, 2006.
56. Lin YG, Kunnumakkara AB, Nair A, Merritt WM, Han LY,
Armaiz-Pena GN, Kamat AA, Spannuth WA, Gershenson DM,
Lutgendorf SK, et al: Curcumin inhibits tumor growth and
angiogenesis in ovarian carcinoma by targeting the nuclear
factor-kappaB pathway. Clin Cancer Res 13: 3423-3430, 2007.
57. Gonzalez-Perez RR, Xu Y, Guo S, Watters A, Zhou W and
Leibovich SJ: Leptin upregulates VEGF in breast cancer via
canonic and non-canonical signalling pathways and NFkappaB/
HIF-1alpha activation. Cell Signal 22: 1350-1362, 2010.
58. Testa JR and Bellacosa A: AKT plays a central role in tumorigenesis. Proc Natl Acad Sci USA 98: 10983-10985, 2001.
59. Cain K, Langlais C, Sun XM, Brown DG and Cohen GM:
Physiological concentrations of K+ inhibit cytochrome
c-dependent formation of the apoptosome. J Biol Chem 276:
41985-41990, 2001.
60. Arafa SA, Zhu Q, Barakat BM, Wani G, Zhao Q, El-Mahdy MA
and Wani AA: Tangeretin sensitizes cisplatin-resistant human
ovarian cancer cells through downregulation of phosphoinositide
3-kinase/Akt signaling pathway. Cancer Res 69: 8910-8917,
2009.
61. Luo H, Daddysman MK, Rankin GO, Jiang BH and Chen YC:
Kaempferol enhances cisplatin's effect on ovarian cancer cells
through promoting apoptosis caused by down regulation of
c-Myc. Cancer Cell Int 10: 16, 2010.

